In other Early-Ad cases, MET (Y1021N, exon 14 splice site, exon 14 deletion), KRAS (G12A, G12D)16, BRAF (A489_Q493del)17, ERBB2 (V659E)18, and MAP2K1 (E102_I103del)19 mutations, and RET (KIF5B-RET) and ALK (EML4-ALK) fusions were detected as other driver aberrations20–23. Here, MAP2K1 is linked to Alzheimer disease.